Publications

  1. Kayser S, Martínez-Cuadrón D, Hanoun M, Stölzel F, Gil C, Reinhardt HC, Aguiar E, Schäfer-Eckart K, Burgues JMB, Steffen B, Bernal T, Krause SW, Riaza R, Schliemann C, Cervera J, Kaufmann M, Torres-Miñana L, Hänel M, Acuña-Cruz E, Jost E, Algarra JL, Crysandt M, Fransecky L, Cornago-Navascues J, Kraus S, Martinez-Lopez J, Einsele H, Niemann D, Neubauer A, Seggewiß-Bernhardt R, Scholl S, Klein SA, Schmid C, Schaich M, Schmidt-Hieber M, Zukunft S, Ho AD, Platzbecker U, Baldus CD, Müller-Tidow C, Thiede C, Bornhäuser M, Serve H, Levis M, Montesinos P, Röllig C, Schlenk RF: Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4. Haematologica. 2022 Jun 9. Online ahead of print.
  2. Pindzola GM, Razzaghi R, Tavory RN, Nguyen HT, Morris VM, Li M, Agarwal S, Huang B, Okada T, Reinhardt HC, Knittel G, Kashkar H, Young RM, Pittaluga S, Muppidi JR: Aberrant expansion of spontaneous splenic germinal centers induced by hallmark genetic lesions of aggressive lymphoma. Blood. 2022 Jun 27:blood.2022015926. Online ahead of print.
  3. Ullrich F, Hanoun C, Turki AT, Liebregts T, Breuckmann K, Alashkar F, Reinhardt HC, von Tresckow B, von Tresckow J: Early report on the severity of COVID-19 in hematologic patients infected with the SARS-CoV2 omicron variant. Eur J Haematol. 2022 Jun 25. Online ahead of print.
  4. Ratz L, Brambillasca C, Bartke L, Huetzen MA, Goergens J, Leidecker O, Jachimowicz RD, van de Ven M, Proost N, Siteur B, de Korte-Grimmerink R, Bouwman P, Pulver EM, de Bruijn R, Isensee J, Hucho T, Pandey G, van Lohuizen M, Mallmann P, Reinhardt HC, Jonkers J, Puppe J: Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer. Breast Cancer Res. 2022 Jun 17;24(1):41.
  5. Thomalla D, Beckmann L, Grimm C, Oliverio M, Meder L, Herling CD, Nieper P, Feldmann T, Merkel O, Lorsy E, da Palma Guerreiro A, von Jan J, Kisis I, Wasserburger E, Claasen J, Faitschuk-Meyer E, Altmüller J, Nürnberg P, Yang TP, Lienhard M, Herwig R, Kreuzer KA, Pallasch CP, Buettner R, Schäfer SC, Hartley J, Abken H, Peifer M, Kashkar H, Knittel G, Eichhorst B, Ullrich RT, Herling M, Reinhardt HC, Hallek M, Schweiger MR, Frenzel LP: Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies. Blood. 2022 Jun 15:blood.2021014304. Online ahead of print.
  6. Aramayo-Singelmann C, Halimeh S, Proske P, Vignalingarajah A, Cario H, Christensen MO, Yamamoto R, Röth A, Reinhardt D, Reinhardt HC, Alashkar F: Screening and diagnosis of hemoglobinopathies in Germany: Current state and future perspectives. Sci Rep. 2022 Jun 13;12(1):9762.
  7. Röth A, Bertram S, Schroeder T, Haverkamp T, Voigt S, Holtkamp C, Klump H, Wörmann B, Reinhardt HC, Alashkar F: Acquired aplastic anemia following SARS-CoV-2 vaccination. Eur J Haematol. 2022 Aug;109(2):186-194. Epub 2022 Jun 1.
  8. Nagler A, Peczynski C, Dholaria B, Labopin M, Valerius T, Dreger P, Kröger N, Reinhardt HC, Finke J, Franke GN, Ciceri F, Verbeek M, Blau IW, Bornhäuser M, Spyridonidis A, Bug G, Bazarbachi A, Schmid C, Yakoub-Agha I, Savani BN, Mohty M: Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemia. Bone Marrow Transplant. 2022 Jul;57(7):1116-1123. Epub 2022 Apr 30.
  9. Thimm A, Carpinteiro A, Oubari S, Papathanasiou M, Kessler L, Rischpler C, Malik RA, Reinhardt HC, Rassaf T, Herrmann K, Kleinschnitz C, Stettner M, Hagenacker T: Corneal confocal microscopy to detect early immune-mediated small nerve fibre loss in AL amyloidosis. Ann Clin Transl Neurol. 2022 Jun;9(6):853-863. Epub 2022 Apr 30.
  10. Kadow S, Schumacher F, Kramer M, Hessler G, Scholtysik R, Oubari S, Johansson P, Hüttmann A, Reinhardt HC, Kleuser B, Zoratti M, Mattarei A, Szabò I, Gulbins E, Carpinteiro A: Mitochondrial Kv1.3 Channels as Target for Treatment of Multiple Myeloma. Cancers (Basel). 2022 Apr 13;14(8):1955
  11. Izquierdo E, Vorholt D, Blakemore S, Sackey B, Nolte JL, Barbarino V, Schmitz J, Nickel N, Bachurski D, Lobastova L, Nikolic M, Michalik M, Brinker R, Merkel O, Franitza M, Georgomanolis T, Neuhaus R, Koch M, Nasada N, Knittel G, Chapuy B, Ludwig N, Meese E, Frenzel L, Reinhardt HC, Peifer M, Rebollido-Rios R, Bruns H, Krüger M, Hallek M, Pallasch CP: Extracellular vesicles and PD-L1 suppress macrophages, inducing therapy resistance in TP53-deficient B-cell malignancies. Blood. 2022 Jun 23;139(25):3617-3629.
  12. Werr L, Plenker D, Dammert MA, Lorenz C, Brägelmann J, Tumbrink HL, Klein S, Schmitt A, Büttner R, Persigehl T, Shokat KM, Wunderlich FT, Schram AM, Peifer M, Sos ML, Reinhardt HC*, Thomas RK*: CD74-NRG1 Fusions Are Oncogenic In Vivo and Induce Therapeutically Tractable ERBB2:ERBB3 Heterodimerization. Mol Cancer Ther. 2022 May 4;21(5):821-830. * shared last authors
  13. Gagelmann N, Wolschke C, Salit RB, Schroeder T, Ditschkowski M, Panagiota V, Cassinat B, Thol F, Badbaran A, Robin M, Reinhardt HC, Ayuk F, Heuser M, Scott BL, Kröger N: Reduced intensity hematopoietic stem cell transplantation for myelofibrosis in accelerated-phase. Blood Adv. 2022 Jan 20:bloodadvances.2021006827. Online ahead of print.
  14. Rodriguez S, Celay J, Goicoechea I, Jimenez C, Botta C, Garcia-Barchino MJ, Garces JJ, Larrayoz M, Santos S, Alignani D, Vilas-Zornoza A, Perez C, Garate S, Sarvide S, Lopez A, Reinhardt HC, Carrasco YR, Sanchez-Garcia I, Larrayoz MJ, Calasanz MJ, Panizo C, Prosper F, Lamo-Espinosa JM, Motta M, Tucci A, Sacco A, Gentile M, Duarte S, Vitoria H, Geraldes C, Paiva A, Puig N, Garcia-Sanz R, Roccaro AM, Fuerte G, San Miguel JF, Martinez-Climent JA, Paiva B: Preneoplastic somatic mutations including MYD88L265P in lymphoplasmacytic lymphoma. Sci Adv. 2022 Jan 21;8(3):eabl4644. Epub 2022 Jan 19.
  15. Bazarbachi A, Labopin M, Aljurf M, Niittyvuopio R, Balsat M, Blaise D, Yakoub-Agha I, Grassi A, Reinhardt HC, Lenhoff S, Jindra P, Passweg J, Abou Dalle I, Stadler M, Lioure B, Ceballos P, Brissot E, Giebel S, Nagler A, Schmid C, Mohty M: 20-Year Steady Increase in Survival of Adult Patients with Relapsed Philadelphia-Positive Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Cell Transplantation. Clin Cancer Res. 2022 Jan 12. Online ahead of print.
  16. Farber M, Chen Y, Arnold L, Möllmann M, Boog-Whiteside E, Lin YA, Reinhardt HC, Dührsen U, Hanoun M: Targeting CD38 in acute myeloid leukemia interferes with leukemia trafficking and induces phagocytosis. Sci Rep. 2021 Nov 11;11(1):22062.
  17. Leypoldt LB, Besemer B, Asemissen AM, Hänel M, Blau IW, Görner M, Ko YD, Reinhardt HC, Staib P, Mann C, Lutz R, Munder M, Graeven U, Peceny R, Salwender H, Jauch A, Zago M, Benner A, Tichy D, Bokemeyer C, Goldschmidt H, Weisel KC: Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial. Leukemia. 2021 Nov 3. PMID: 34732857. [Epub ahead of print]
  18. Lindemann M, Klisanin V, Thümmler L, Fisenkci N, Tsachakis-Mück N, Ditschkowski M, Schwarzkopf S, Klump H, Reinhardt HC, Horn PA, Koldehoff M: Humoral and Cellular Vaccination Responses against SARS-CoV-2 in Hematopoietic Stem Cell Transplant Recipients. Vaccines (Basel). 2021 Sep 25;9(10):1075.
  19. Kordelas L, Buttkereit U, Heinemann FM, Horn PA, Giebel B, Beelen DW, Reinhardt HC, Rebmann V: Low Soluble Programmed Cell Death Protein 1 Levels After Allogeneic Stem Cell Transplantation Predict Moderate or Severe Chronic GvHD and Inferior Overall Survival. Front Immunol. 2021 Sep 24;12:694843.
  20. Wilke AC, Doebele C, Zindel A, Lee KS, Rieke SA, Ceribelli M, Comoglio F, Phelan JD, Wang JQ, Pikman Y, Jahn D, Häupl B, Schneider C, Scheich S, Tosto FA, Bohnenberger H, Stauder P, Schnuetgen F, Slabicki M, Coulibaly ZA, Wolf S, Bojarczuk K, Chapuy B, Brandts CH, Stroebel P, Lewis CA, Engelke M, Xu X, Kim H, Dang TH, Schmitz R, Hodson DJ, Stegmaier K, Urlaub H, Serve H, Schmitt CA, Kreuz F, Knittel G, Rabinowitz JD, Reinhardt HC, Vander Heiden MG, Thomas C, Staudt LM, Zenz T, Oellerich T: SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma. Blood. 2020 Oct 8: blood.2021012081. doi: 10.1182/blood.2021012081. PMID: 34624079. [Epub ahead of print]
  21. Proske P, Distelmaier L, Aramayo-Singelmann C, Koliastas N, Iannaccone A, Papathanasiou M, Temme C, Klump H, Lenz V, Koldehoff M, Carpinteiro A, Reinhardt HC, Köninger A, Röth A, Yamamoto R, Dührsen U, Alashkar F: Pregnancies and Neonatal Outcomes in Patients with Sickle Cell Disease (SCD): Still a (High-)Risk Constellation? J Pers Med. 2021 Aug 30;11(9):870.
  22. Schmidt J, Goergens J, Pochechueva T, Kotter A, Schwenzer N, Sitte M, Werner G, Altmüller J, Thiele H, Nürnberg P, Isensee J, Li Y, Müller C, Leube B, Reinhardt HC, Hucho T, Salinas G, Helm M, Jachimowicz RD, Wieczorek D, Kohl T, Lehnart SE, Yigit G, Wollnik B: Biallelic variants in YRDC cause a developmental disorder with progeroid features. Hum Genet. 2021 Dec;140(12):1679–1693.
  23. Pacholewska A, Grimm C, Herling CD, Lienhard M, Königs A, Timmermann B, Altmüller J, Mücke O, Reinhardt HC, Plass C, Herwig R, Hallek M, Schweiger MR: Altered DNA Methylation Profiles in SF3B1-Mutated CLL Patients. Int J Mol Sci. 2021 Aug 28;22(17):9337.
  24. von Tresckow J, von Tresckow B, Reinhardt HC, Herrmann K, Berliner C: Thymic hyperplasia after mRNA based Covid-19 vaccination. Radiol Case Rep. 2021 Dec;16(12):3744–3745.
  25. Baron F, Ngoya M, Labopin M, Cornelissen JJ, Ganser A, Forcade E, Sengeloev H, Socié G, Blaise D, Bornhäuser M, Valerius T, Reinhardt HC, Kröger N, Ruggeri A, Nagler A, Mohty M: Comparison of long-term outcome for AML patients alive free of disease 2 years after allogeneic hematopoietic cell transplantation with umbilical cord blood versus unrelated donor: a study from the ALWP of the EBMT. Bone Marrow Transplant. 2021 Nov;56(11):2742–2748.
  26. Mülling N, Rosery V, Reinhardt HC, Hanoun M: Factor IX p.A37V mutation causes severe bleeding in a patient with phenprocoumon therapy. Eur J Med Res. 2021 Jun 29;26(1):63.
  27. Oubari S, Naser E, Papathanasiou M, Luedike P, Hagenacker T, Thimm A, Rischpler C, Kessler L, Kimmich C, Hegenbart U, Schönland S, Rassaf T, Reinhardt HC, Jöckel KH, Dürig J, Dührsen U, Carpinteiro A: Impact of time to diagnosis on Mayo stages, treatment outcome, and survival in patients with AL amyloidosis and cardiac involvement. Eur J Haematol. 2021 Oct;107(4):449–457.
  28. Jachimowicz RD, Klapper W, Glehr G, Müller H, Haverkamp H, Thorns C, Hansmann ML, Möller P, Stein H, Rehberg T, von Tresckow B, Reinhardt HC, Borchmann P, Chan FC, Spang R, Scott DW, Engert A, Steidl C, Altenbuchinger M, Rosenwald A: Gene expression-based outcome prediction in advanced stage classical Hodgkin lymphoma treated with BEACOPP. Leukemia. 2021 Jun 10. doi: 10.1038/s41375-021-01314-1. PMID: 34112956. [Epub ahead of print]
  29. Kanne J, Hussong M, Isensee J, Muñoz-López Á, Wolffgramm J, Heß F, Grimm C, Bessonov S, Meder L, Wang J, Reinhardt HC, Odenthal M, Hucho T, Büttner R, Summerer D, Schweiger MR: Pericentromeric Satellite III transcripts induce etoposide resistance. Cell Death Dis. 2021 May 24;12(6):530.
  30. McLornan D, Eikema DJ, Czerw T, Kröger N, Koster L, Reinhardt HC, Angelucci E, Robin M, Bornhäuser M, Passweg J, Clark A, Vydra J, Blau IE, Niittyvuopio R, Platzbecker U, Cornelissen JJ, Chevallier P, Srour M, Stamatovic D, Martinez-Lopez J, de Wreede L, Hayden P, Hernández-Boluda JC, Yakoub-Agha I: Trends in allogeneic haematopoietic cell transplantation for myelofibrosis in Europe between 1995 and 2018: a CMWP of EBMT retrospective analysis. Bone Marrow Transplant. 2021 Apr 28. doi: 10.1038/s41409-021-01305-x.[Epub ahead of print]
  31. Bebber CM, Thomas ES, Stroh J, Chen Z, Androulidaki A, Schmitt A, Höhne MN, Stüker L, de Pádua Alves C, Khonsari A, Dammert MA, Parmaksiz F, Tumbrink HL, Beleggia F, Sos ML, Riemer J, George J, Brodesser S, Thomas RK, Reinhardt HC, von Karstedt S: Ferroptosis response segregates small cell lung cancer (SCLC) neuroendocrine subtypes. Nat Commun. 2021 Apr 6;12(1):2048.
  32. Subramaniam N, Bottek J, Thiebes S, Zec K, Kudla M, Soun C, de Dios Panal E, Lill JK, Pfennig A, Herrmann R, Bruderek K, Rahmann S, Brandau S, Johansson P, Reinhardt HC, Dürig J, Seiffert M, Bracht T, Sitek B, Engel DR: Proteomic and bioinformatic profiling of neutrophils in CLL reveals functional defects that predispose to bacterial infections. Blood Adv. 2021 Mar 9;5(5):1259–1272.
  33. Kohlhaas V, Blakemore SJ, Al-Maarri M, Nickel N, Pal M, Roth A, Hövelmeyer N, Schäfer SC, Knittel G, Lohneis P, Nikolic M, Wiederstein JL, Franitza M, Georgomonolis T, Reinart N, Herling M, Herling C, Hartmann EM, Rosenwald A, Klapper W, Büttner R, Moia R, Rossi D, Boldorini R, Gaidano G, Frenzel LP, Reinhardt HC, Brüning JC, Hallek M, Krüger M, Peifer M, Pallasch CP, Wunderlich FT: Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1. Blood. 2021 Feb 4;137(5):646–660.
  34. Lennartz S, Mager A, Große Hokamp N, Schäfer S, Zopfs D, Maintz D, Reinhardt HC, Thomas RK, Caldeira L, Persigehl T: Texture analysis of iodine maps and conventional images for k-nearest neighbor classification of benign and metastatic lung nodules. Cancer Imaging. 2021 Jan 26;21(1):17.
  35. Flümann R, Rehkämper T, Nieper P, Pfeiffer P, Holzem A, Klein S, Bhatia S, Kochanek M, Kisis I, Pelzer BW, Ahlert H, Hauer J, da Palma Guerreiro A, Ryan JA, Reimann M, Riabinska A, Wiederstein J, Krüger M, Deckert M, Altmüller J, Klatt AR, Frenzel LP, Pasqualucci L, Béguelin W, Melnick AM, Sander S, Montesinos-Rongen M, Brunn A, Lohneis P, Büttner R, Kashkar H, Borkhardt A, Letai A, Persigehl T, Peifer M, Schmitt CA, Reinhardt HC*,#, Knittel G*: An Autochthonous Mouse Model of Myd88- and BCL2-Driven Diffuse Large B-cell Lymphoma Reveals Actionable Molecular Vulnerabilities. Blood Cancer Discov. 2021 Jan;2(1):70–91. *shared last authors, #corresponding author
  36. Klein S, Quaas A, Quantius J, Löser H, Meinel J, Peifer M, Wagner S, Gattenlöhner S, Wittekindt C, von Knebel Doeberitz M, Prigge ES, Langer C, Noh KW, Maltseva M, Reinhardt HC, Büttner R, Klussmann JP, Wuerdemann N: Deep Learning Predicts HPV Association in Oropharyngeal Squamous Cell Carcinomas and Identifies Patients with a Favorable Prognosis Using Regular H&E Stains. Clin Cancer Res. 2021 Feb 15;27(4):1131–1138.
  37. Reimann M, Schrezenmeier J, Richter-Pechanska P, Dolnik A, Hick TP, Schleich K, Cai X, Fan DNY, Lohneis P, Maßwig S, Denker S, Busse A, Knittel G, Flümann R, Childs D, Childs L, Gätjens-Sanchez AM, Bullinger L, Rosenwald A, Reinhardt HC, Schmitt CA: Adaptive T-cell immunity controls senescence-prone MyD88- or CARD11-mutant B-cell lymphomas. Blood. 2021 May 20;137(20):2785–2799.
  38. Zimmer Y, Reinhardt HC, Medová M: Editorial: Exploiting DNA Damage Response in the Era of Precision Oncology. Front Oncol. 2020 Oct 15;10:611127.
  39. Chen Y, Hoffmeister LM, Zaun Y, Arnold L, Schmid KW, Giebel B, Klein-Hitpass L, Hanenberg H, Squire A, Reinhardt HC, Dührsen U, Bertram S, Hanoun M: Acute myeloid leukemia-induced remodeling of the human bone marrow niche predicts clinical outcome. Blood Adv. 2020 Oct 27;4(20):5257–5268.
  40. Jakobs F, Drost RMWA, Kron A, Heinen J, Hallek M, Reinhardt HC, Zander T, Kron F: Economic Impact of the Introduction of Outpatient Medical Specialist Care (ASV) of Gastrointestinal Cancer Patients from a German Hospital Management Perspective. Oncol Res Treat. 2020;43(10):498–505.
  41. Gremke N, Polo P, Dort A, Schneikert J, Elmshäuser S, Brehm C, Klingmüller U, Schmitt A, Reinhardt HC, Timofeev O, Wanzel M, Stiewe T: mTOR-mediated cancer drug resistance suppresses autophagy and generates a druggable metabolic vulnerability. Nat Commun. 2020 Sep 17;11(1):4684.
  42. Johansson P, Klein-Hitpass L, Röth A, Möllmann M, Reinhardt HC, Dührsen U, Dürig J: Mutations in PIGA cause a CD52-/GPI-anchor-deficient phenotype complicating alemtuzumab treatment in T-cell prolymphocytic leukemia. Eur J Haematol. 2020 Dec;105(6):786–796.
  43. Schödel P, Jünger ST, Wittersheim M, Reinhardt HC, Schmidt NO, Goldbrunner R, Proescholdt M, Grau S: Surgical resection of symptomatic brain metastases improves the clinical status and facilitates further treatment. Cancer Med. 2020 Oct;9(20):7503–7510.
  44. Klein S, Quaas A, Noh KW, Cartolano M, Abedpour N, Mauch C, Quantius J, Reinhardt HC, Buettner R, Peifer M, Helbig D: Integrative Analysis of Pleomorphic Dermal Sarcomas Reveals Fibroblastic Differentiation and Susceptibility to Immunotherapy. Clin Cancer Res. 2020 Nov 1;26(21):5638–5645.
  45. Kong YW, Dreaden EC, Morandell S, Zhou W, Dhara SS, Sriram G, Lam FC, Patterson JC, Quadir M, Dinh A, Shopsowitz KE, Varmeh S, Yilmaz ÖH, Lippard SJ, Reinhardt HC, Hemann MT, Hammond PT, Yaffe MB: Enhancing chemotherapy response through augmented synthetic lethality by co-targeting nucleotide excision repair and cell-cycle checkpoints. Nat Commun. 2020 Aug 17;11(1):4124.
  46. Koch M, Reinartz S, Saggau J, Knittel G, Rosen N, Fedorchenko O, Thelen L, Barthel R, Reinart N, Seeger-Nukpezah T, Reinhardt HC, Hallek M, Nguyen PH: Meta-Analysis Reveals Significant Sex Differences in Chronic Lymphocytic Leukemia Progression in the Eµ-TCL1 Transgenic Mouse Model. Cancers(Basel). 2020 Jul 20;12(7):1980.
  47. Spiro JE, Rinneburger M, Hedderich DM, Jokic M, Reinhardt HC, Maintz D, Palmowski M, Persigehl T: Monitoring treatment effects in lung cancer-bearing mice: clinical CT and clinical MRI compared to micro-CT. Eur Radiol Exp. 2020 May 13;4(1):31.
  48. Jachimowicz RD, Pieper L, Reinke S, Gontarewicz A, Plütschow A, Haverkamp H, Frauenfeld L, Fend F, Overkamp M, Jochims F, Thorns C, Leo Hansmann M, Möller P, Rosenwald A, Stein H, Reinhardt HC, Borchmann P, von Tresckow B, Engert A, Klapper W: Whole-slide image analysis of the tumor microenvironment identifies low B-cell content as a predictor of adverse outcome in patients with advanced-stage classical Hodgkin lymphoma treated with BEACOPP. Haematologica. 2021 Jun 1;106(6):1684–1692.
  49. Volz C, Breid S, Selenz C, Zaplatina A, Golfmann K, Meder L, Dietlein F, Borchmann S, Chatterjee S, Siobal M, Schöttle J, Florin A, Koker M, Nill M, Ozretić L, Uhlenbrock N, Smith S, Büttner R, Miao H, Wang B, Reinhardt HC, Rauh D, Hallek M, Acker-Palmer A, Heukamp LC, Ullrich RT: Inhibition of Tumor VEGFR2 Induces Serine 897 EphA2-Dependent Tumor Cell Invasion and Metastasis in NSCLC. Cell Rep. 2020 Apr 28;31(4):107568.
  50. Flümann R, Nieper P, Reinhardt HC*,#, Knittel G#: New murine models of aggressive lymphoma. Leukemia Lymphoma, 2020 Apr;61(4):788–798. #shared last authors, *corresponding author
  51. Erber J, Steiner JD, Isensee J, Lobbes LA, Toschka A, Beleggia F, Schmitt A, Kaiser RWJ, Siedek F, Persigehl T, Hucho T, Reinhardt HC: Dual inhibition of GLUT1 and the ATR/CHK1 kinase axis displays synergistic cytotoxicity in KRAS-mutant cancer cells. Cancer Res. 2019 Aug 12. pii: canres.3959.2018. doi: 10.1158/0008-5472.CAN-18-3959.
  52. Schuldner M, Dorsam B, Shatnyeva O, Reiners KS, Kubarenko A, Hansen HP, Finkernagel F, Roth K, Theurich S, Nist A, Stiewe T, Paschen A, Knittel G, Reinhardt HC, Müller R, Hallek M, Pogge von Strandmann: Exosome-dependent immune surveillance at the metastatic niche requires BAG6 and CBP/p300-dependent acetylation of p53, Theranostics, Aug 14;9(21):6047–6062. doi: 10.7150/thno.36378. eCollection 2019.
  53. Roderwieser A, Sand F, Walter E, Fischer J, Gecht J, Bartenhagen C, Ackermann S, Otte F, Welte A, Kahlert Y, Lieberz D, Hertwig F, Reinhardt HC, Simon T, Peifer M, Ortmann M, Büttner R, Hero B, O’Sullivan RJ, Berthold F, Fischer M: Telomerase is a prognostic marker of poor outcome and a therapeutic target in neuroblastoma. JCO Precision Oncology, accepted for publication.
  54. Riabinska A, Lehrmann D, Jachimowicz RD, Knittel G, Fritz C, Schmitt A, Geyer A, Heneweer C, Wittersheim M, Frenzel LP, Torgovnick A, Wiederstein JL, Wunderlich CM, Ortmann M, Paillard A, Wößmann W, Borkhardt A, Burdach S, Hansmann M-L, Rosenwald A, Perner S, Mall G, Klapper W, Merseburg A, Krüger M, Grüll H, Persigehl T, Wunderlich FT, Peifer M, Utermöhlen O, Büttner R, Beleggia F, Reinhardt HC: ATM activity in T cells is critical for immune surveillance of lymphoma in vivo, Leukemia, Mar;34(3):771–786. doi: 10.1038/s41375-019-0618-2. Epub 2019 Nov 5.
  55. Bendell JC, Bischoff HG, Hwang J, Reinhardt HC, Zander T, Wang X, Hynes S, Pitou C, Campbell R, Iversen P, Farrington DL, Bell-McGuinn K, Thomas M: A Phase 1 Dose-Escalation Study of Checkpoint Kinase 1 (CHK1) Inhibitor Prexasertib in Combination with p38 Mitogen-Activated Protein Kinase (p38 MAPK) Inhibitor Ralimetinib in Patients with Advanced or Metastatic Cancer. Investigational New Drugs, 2020 Aug;38(4):1145–1155.
  56. Dammert MA, Brägelmann J, Olsen RR, Böhm S, Monhasery N, Whitney CP, Chalishazar MD, Tumbrink HL, Guthrie MR, Klein S, Ireland AS, Ryan J, Schmitt A, Marx A, Ozretić L, Castiglione R, Lorenz C, Jachimowicz RD, Wolf E, Thomas RK, Poirier JT, Buttner R, Sen T, Byers LA, Reinhardt HC, Letai A, Oliver TG, Sos ML: MYC paralog-dependent 1 apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer. Nature Communications, 2019 Aug 2;10(1):3485.
  57. Kreuzer KA, Furman RR, Stilgenbauer S, Dubowy RL, Kim Y, Munugalavadla V, Lilienweiss E, Reinhardt HC, Cramer P, Eichhorst B, Hillmen P, O’Brien SM, Pettitt AR, Hallek M: The Impact of Complex Karyotype on the Overall Survival of Patients with Relapsed Chronic Lymphocytic Leukemia Treated with Idelalisib Plus Rituximab. Leukemia, 2020 Jan;34(1):296–300.
  58. Jachimowicz RD, Goergens J, Reinhardt HC: DNA double-strand break repair pathway choice – from basic biology to clinical exploitation. Cell Cycle. 2019 Jul;18(13):1423–1434.
  59. Puppe J, Opdam M, Schouten PC, Jóźwiak K, Lips EH, Severson T, van de Ven M, Brambillasca CS, Bouwman P, van Tellingen O, Bernards R, Wesseling J, Eichler C, Thangarajah F, Malter W, Pandey GK, Ozretić L, Caldas C, van Lohuizen M, Hauptmann M, Rhiem K, Hahnen E, Reinhardt HC, Büttner R, Mallmann P, Schömig-Markiefka B, Schmutzler RK, Linn SC, Jonkers J: EZH2 is overexpressed in BRCA1-like breast tumors and predictive for sensitivity to high-dose platinum-based chemotherapy. Clin Cancer Res. 2019 Apr 29. doi: 10.1158/1078-0432.CCR-18-4024. [Epub ahead of print]
  60. Jachimowicz RD, Reinhardt HC: UBQLN4 promotes non-homologous end joining by repressing DNA end-resection. Molecular & Cellular Oncology, 2019 Feb 20;6(2):1575692.
  61. Castiglione R, Alidousty C, Holz B, Wagener S, Baar T, Heydt C, Binot E, Zupp S, Kron A, Wolf J, Merkelbach-Bruse S, Reinhardt HC, Büttner R, Schultheis AM: Comparison of the genomic background of MET-altered carcinomas of the lung: biological differences and analogies. Modern Pathology, 2018 Nov 20. doi: 10.1038/s41379-018-0182-8.
  62. Jachimowicz RD, Beleggia F, Isensee J, Bhavana VB, Goergens J, Bustos MA, Doll MA, Shenoy A, Checa-Rodriguez C, Wiederstein JL, Baranes-Bachar K, Bartenhagen C, Hertwig F, Teper N, Nishi T, Schmitt A, Distelmaier F, Lüdecke HJ, Albrecht B, Krüger M, Schumacher B, Geiger T, Hoon DSB, Huertas P, Fischer M, Hucho T, Peifer M, Ziv Y, Reinhardt HC*,#, Wieczorek D*, Shiloh Y*: UBQLN4 represses homologous recombination and is overexpressed in aggressive tumors, Cell, 2018 Dec 21. pii: S0092-8674(18)31516-2. doi: 10.1016/j.cell.2018.11.024., *shared last authors, #lead author contact
  63. Grimm C, Fischer A, Farrelly AM, Kalachand R, Castiglione R, Wasserburger E, Hussong M, Schultheis A, Altmüller J, Thiele H, Reinhardt HC, Hauschulz K, Hennessy BT, Herwig R, Lienhard M, Büttner R, Schweiger MR: Combined targeted re-sequencing of cytosine DNA methylations and mutations for the determination of PARP1 inhibitor sensitivity. The Journal of Molecular Diagnostics, 2018 Dec 18. pii: S1525-1578(18)30247-2. doi: 10.1016/j.jmoldx.2018.10.007.
  64. Torgovnick A, Schiavi A, Shaik A, Kassahun H, Maglioni S, Rea SL, Johnson TE, Reinhardt HC, Honnen S, Schumacher B, Nilsen H, Ventura N: BRCA1/BARD1 mediate apoptotic resistance but not longevity upon mitochondrial stress in C. elegans, EMBO Reports, 2018 Oct 26. pii: e45856. doi: 10.15252/embr.201845856. [Epub ahead of print]
  65. Torgovnick A, Heger JM, Liaki V, Isensee J, Schmitt A, Knittel G, Riabinska A, Beleggia F, Laurien L, Leeser U, Jüngst C, Siedek F, Vogel W, Klümper N, Nolte H, Wittersheim M, Tharun L, Castiglione R, Krüger M, Schauss A, Perner S, Pasparakis M, Büttner R, Persigehl T, Hucho T, Herter-Sprie GS, Schumacher B, Reinhardt HC: The Cdkn1aSUPER mouse as a novel tool to study p53-mediated tumor suppression. Cell Reports, 2018 Oct 23;25(4):1027–1039.e6.
  66. Weber ANR, Gloria YC, Çınar Ö, Reinhardt HC, Pezzutto A, Wolz O-O: Oncogenic MYD88 mutations in lymphoma – novel insights and therapeutic possibilities. Cancer Immunology, Immunotherapy, 2018 Nov;67(11):1797–1807.
  67. Schmitt A, Feldmann G, Zander T, Reinhardt HC: Targeting defects in the cellular DNA damage response for the treatment of pancreatic ductal adenocarcinoma, Oncology Research and Treatment, 2018;41(10):619–625.
  68. Fassunke J, Muller F, Keul M, Michels S, Dammert MA, Schmitt A, Plenker D, Lategahn J, Heydt C, Brägelmann J, Tumbrink HL, Alber Y, Klein S, Dahmen I, Fischer RN, Scheffler M, Ihle MA, Priesner V, Scheel AH, Wagener S, Kron A, Frank K, Garbert K, Persigehl T, Püsken M, Haneder S, Schaaf B, Rodermann E, Engel-Riedel W, Felip E, Smit EF, Merkelbach-Bruse S, Reinhardt HC, Kast SM, Wolf J, Rauh D, Büttner R, Sos ML: Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors. Nature Communications, 2018 Nov 7;9(1):4655.
  69. Yang D, Denny SK, Greenside PG, Chaikovsky AC, Brady JJ, Ouadah Y, Granja JM, Jahchan NS, Lim JS, Kwok S, Kong CS, Berghoff AS, Schmitt A, Reinhardt HC, Park K-S, Preusser M, Kundaje A, Greenleaf W, Sage J, Winslow MM: Inter-tumoral heterogeneity in SCLC is influenced by the cell-type of origin. Cancer Discovery, 2018 Oct;8(10):1316–1331.
  70. Meder L, Schuldt P, Thelen M, Schmitt A, Dietlein F, Klein S, Borchmann S, Wennhold K, Vlasic I, Oberbeck S, Riedel R, Florin A, Golfmann K, Schlößer HA, Odenthal M, Büttner R, Wolf J, Hallek M, Herling M, von Bergwelt-Baildon M, Reinhardt HC, Ullrich RT: Combined VEGF and PD-L1 blockade displays synergistic treatment effects in an autochthonous mouse model of small cell lung cancer. Cancer Research, 2018 May 18. pii: canres.2176.2017. doi: 10.1158/0008-5472.CAN-17-2176. [Epub ahead of print]
  71. Knittel G, Rehkämper T, Nieper P, Schmitt A, Flümann R, Reinhardt HC: DNA damage pathways and B-cell lymphomagenesis. Current Opinion in Hematology, 2018 Apr 26. doi: 10.1097/MOH.0000000000000433. [Epub ahead of print]
  72. Herling CD, Abedpour N, Weiss J, Schmitt A, Jachimowicz RD, Merkel O, Cartolano M, Oberbeck S, Mayer P, Berg V, Thomalla D, Kutsch N, Stiefelhagen M, Cramer P, Wendtner C-M, Persigehl T, Saleh A, Altmüller J, Nürnberg P, Pallasch C, Achter V, Lang U, Eichhorst E, Castiglione R, Schäfer SC, Büttner R, Kreuzer KA, Reinhardt HC, Hallek M, Frenzel LP, Peifer M: Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia. Nature Communications, 2018 Feb 20;9(1):727.
  73. Welcker D, Jain M, Khurshid S, Jokic M, Höhne M, Schmitt A, Frommolt P, Niessen C, Spiro J, Persigehl T, Wittersheim M, Büttner R, Fanciulli M, Schermer B, Reinhardt HC*,#, Benzing T*,#, Hopker K#: AATF suppresses apoptosis, promotes proliferation and is critical for KRAS-driven lung cancer, Oncogene, 2018 Jan 11. doi: 10.1038/s41388-017-0054-6., *shared corresponding authors, #shared last authors
  74. Schrader A, Crispatzu G, Oberbeck S, Mayer P, Pützer S, von Jan J, Vasyutina E, Warner K, Weit N, Pflug N, Braun T, Andersson E, Yadav B, Riabinska A, Maurer B, Ventura Ferreira M, Beier F, Altmueller J, Lanasa M, Herling CD, Haferlach T, Stilgenbauer S, Hopfinger G, Peifer M, Brümmendorf T, Nuernberg P, Elenitoba-Johnson K, Zha S, Hallek M, Moriggl R, Reinhardt HC, Stern M-H, Mustjoki S, Newrzela S, Frommolt P, Herling M: Integrated genetic profiles of T-PLL implicate a TCL1/ATM-centered model of aberrant, but actionable damage responses. Nature Communications, 2018 Feb 15;9(1):697.
  75. Doerr F, George J, Schmitt A, Beleggia F, Rehkämper T, Vierkotten S, Walter V, Weber J-P, Thomas RK, Wittersheim M, Buttner R, Persigehl T, Reinhardt HC: Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer. Scientific Reports, 2017 Nov 14;7(1):15511.
  76. Schiller J, Klein S, Engels M, Büttner R, Rybniker J, Fätkenheuer G, Scheid C, Wybranski C, Quaas A*, Reinhardt HC*, Waßermann R*: Case Report: A Cryptosporidium infection in a patient with relapsed T lymphoblastic lymphoma undergoing allogeneic stem cell transplantation. Eur J Haematol, 2017 Nov 15. doi: 10.1111/ejh.12998., *shared last authors
  77. Schmitt A, Knittel G, Welcker D, Yang T-P, George J, Nowak M, Leeser U, Büttner R, Perner S, Peifer M,Reinhardt HC: ATM deficiency is associated with sensitivity to PARP1 and ATR inhibitors in lung adenocarcinoma, Cancer Research, 2017 Jun 1;77(11):3040–3056.
  78. Brägelmann J, Dammert MA, Dietlein F, Heuckmann JM, Choidas A, Böhm S, Richters A, Basu D, Tischler V, Lorenz C, Habenberger P, Fang Z, Ortiz-Cuaran S, Leenders F, Eickhoff J, Koch U, Getlik M, Termathe M, Sallouh M, Greff Z, Varga Z, Balke-Want H, French CA, Peifer M, Reinhardt HC, Örfi L, Kéri G, Ansén S, Heukamp LC, Buttner R, Rauh D, Klebl BM, Thomas RK, Sos ML: Systematic kinase inhibitor profiling identifies CDK9 as a synthetic lethal target in NUT midline carcinoma. Cell Reports, 2017 Sep 19;20(12):2833–2845.
  79. Knittel G, Rehkämper T, Korovkina D, Liedgens P, Fritz C, Torgovnick A, Al-Baldawi Y, Al-Maarri M, Cun Y, Fedorchenko O, Riabinska A, Beleggia F, Nguyen P-H, Wunderlich FT, Ortmann M, Montesinos-Rongen M, Tausch E, Stilgenbauer S, Frenzel L, Herling M, Herling C, Bahlo J, Hallek M, Peifer M, Büttner R, Persigehl T, Reinhardt HC: Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemia. Nature Communications, 2017 Jul 28;8(1):153.
  80. Perkhofer L, Schmitt A, Romero M, Ihle M, Hampp S, Ruess DA, Hessmann E, Russell R, Lechel A, Azoitei N, Lin Q, Liebau S, Hohwieler M, Bohnenberger H, Lesina M, Alguel H, Gieldon L, Schroeck E, Gaedcke J, Wagner M, Wiessmüller L, Sipos B, Seufferlein T, Reinhardt HC, Frappart PO, Kleger A: ATM-deficiency generates genomic instability in pancreatic ductal adenocarcinoma and sensitizes toward therapeutic DNA-damage, Cancer Research, 2017 Oct 15;77(20):5576–5590.
  81. Lohmann G, Vasyutina E, Bloehdorn J, Reinart N, Schneider JI, Babu V, Knittel G, Crispatzu G, Mayer P, Prinz C, Biersack B, Efremov DG, Chessa L, Herling CD, Stilgenbauer S, Hallek M, Schobert R, Reinhardt HC, Schumacher B, Herling M: Targeting transcription-coupled nucleotide excision repair overcomes resistance in chronic lymphocytic leukemia, Leukemia, 2017 May;31(5):1177–1186.
  82. Cramer P, Eichhorst B, Reinhardt HC, Hallek M: Current strategies to create tailored and risk-adapted therapies for CLL patients. Best Pract Res Clin Haematol., 2016 Mar;29(1):111–121.
  83. Knittel G, Liedgens P, Korovkina D, Pallasch CP, Reinhardt HC: Rewired NFκB signaling as an actionable feature of activated B cell-like DLBCL. Eur J Haematol, 2016 Aug 16. doi: 10.1111/ejh.12792. [Epub ahead of print]
  84. Jokić M*, Vlašić I*, Rinneburger M*, Klümper N, Spiro J, Vogel W, Offermann A, Kümpers C, Fritz C, Schmitt A, Riabinska, Wittersheim M, Michels S, Ozretić L, Florin A, Welcker D, Akyuz MD, Nowak M, Erkel M, Wolf J, Büttner R, Schumacher B, Thomale J, Persigehl T, Maintz D, Perner S, Reinhardt HC: Ercc1 Deficiency Promotes Tumorigenesis and Increases Cisplatin Sensitivity in a TP53 Context-specific Manner. Molecular Cancer Research, 2016 Aug 11. pii: molcanres.0094.2016. [Epub ahead of print]
  85. Thijssen R, ter Burg J, Garrick B, van Bochove GGW, Brown JR, Fernendes SM, Rodriguez M, Michot JM, Hallek M, Eichhorst BF, Reinhardt HC, Bendell J, Derks IAM, van Kampen R, Hege K, Kersten MJ, Trowe T, Filvaroff E, Eldering E, Kater A: Dual TORK/DNA-PK inhibition blocks critical signalling pathways in chronic lymphocytic leukemia. Blood, 2016 Jul 28;128(4):574–83.
  86. Herling CD, Klaumünzer M, Krings Rocha C, Altmüller J, Thiele H, Bahlo J, Kluth S, Crispatzu G, Herling M, Schiller J, Engelke A, Tausch E, Döhner H, Fischer K, Goede V, Nürnberg P, Reinhardt HC, Stilgenbauer S, Hallek M, Kreuzer K: Complex karyotypes, KRAS and POT1 mutations impact outcome in CLL after chlorambucil based chemo- or chemoimmunotherapy. Blood, 2016 Jul 21;128(3):395–404.
  87. Knittel G, Liedgens P, Korovkina D, Seeger JM, Al-Baldawi Y, Al-Maarri M, Fritz C, Vlantis K, Bezhanova S, Scheel AH, Wolz OO, Reimann M, Möller P, López C, Schlesner M, Lohneis P, Weber ANR, Trümper L, ICGC MMML-Seq Consortium, Staudt LM, Ortmann M, Pasparakis M, Siebert R, Schmitt CA, Klatt AR, Wunderlich FT, Schäfer SC, Persigehl T, Montesinos-Rongen M, Odenthal M, Büttner R, Frenzel LP, Kashkar H, Reinhardt HC: B cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B cell lymphoma in mice. Blood, 2016 Jun 2;127(22):2732–41.
  88. Frenzel LP, Reinhardt HC, Pallasch CP: Concepts of Chronic Lymphocytic Leukemia Pathogenesis: DNA Damage Response and Tumor Microenvironment. Oncol Res Treat, DOI:10.1159/000443820, published online Jan. 22. 2016.
  89. Knittel G, Liedgens P, Reinhardt HC: Targeting ATM-deficient CLL through interference with DNA repair pathways. Frontiers in Genetics, 2015 May 28, doi: 10.3389/fgene.2015.00207
  90. van Vugt MATM, Reinhardt HC: Editorial: Cancer-Associated Defects in the DNA Damage Response: Drivers for Malignant Transformation and Potential Therapeutic Targets. Frontiers in Genetics, 2015 Dec 22, doi: 10.3389/fgene.2015.00355.
  91. George J, Lim JS, Jang SJ, Cun Y, Ozretic L, Leenders F, Lu X, Fernandez-Cuesta L, Bosco G, Nguyen C, Berg J, Müller C, Dahmen I, Jahchan N, Yang D, Karnezis AN, Vaka D, Torres A, Menon R, Wang MS, Stuetz A, Korbel J, Wilkerson M, Hayes N, Engelmann D, Pützer B, Vlasic I, Seidel D, Pinther B, Schaub B, Becker C, Altmüller J, Yokota J, Khono T, Iwakawa R, Muley T, Peterson I, Chen Y, Soltermann A, Tischler V, Massion P, Zou Y, Wright GM, Russell P, Solomon B, Koch I, Field JK, Muscarella LA, La Torre A, Jakopovic M, Knezevic J, Heiden E, Roz L, Jovanovic D, Kontic M, Thunnissen E, Köhler J, Schuler M, Sanchez-Cespedes M, Salvesen H, Achter V, Bogus M, Schneider P, Zander T, Ansén S, Hallek M, Wolf J, Vingron M, Yatabe Y, Travis WD, Nürnberg P, Reinhardt HC, Perner S, Heukamp LC , Büttner R, Haas SA, Brambilla E, Peifer M, Sage J, Thomas RK: Comprehensive genomic profiling of small cell lung cancer. Nature, 2015 Jul 13. doi: 10.1038/nature14664. [Epub ahead of print]
  92. Dietlein F, Kalb B, Jokic M, Noll EM, Strong A, Tharun A, Ozretić L, Künstlinger H, Kambartel K, Randerath WJ, Jüngst C, Schmitt A, Torgovnick A, Richters A, Rauh D, Siedek F, Persigehl T, Mauch C, Bartkova J, Bradley A, Sprick MR, Trumpp A, Rad R, Saur D, Bartek J, Wolf J, Büttner R, Thomas RK, Reinhardt HC: A synergistic interaction between Chk1- and MK2 inhibitors in KRAS-mutant cancer. Cell, 2015 Jul 2;162(1):146–159.
  93. Desantis A, Bruno T, Catena V, De Nicola F, Goeman F, Iezzi S, Sorino C, Gentileschi MP, Germoni S, Monteleone V, Pellegrino M, Kann M, De Meo PD, Pallocca M, Höpker K, Moretti F, Mattei E, Reinhardt HC, Floridi A, Passananti C, Benzing T, Blandino G, Fanciulli M: Che-1 modulates the decision between cell cycle arrest and apoptosis by its binding to p53. Cell Death Dis. 2015 May 21;6:e1764.
  94. Boucas J, Fritz C, Schmitt A, Riabinska A, Thelen L, Peifer M, Leeser U, Nuernberg P, Altmueller J, Gaestel M, Dieterich C, Reinhardt HC: Label-Free Protein-RNA Interactome Analysis Identifies Khsrp Signaling Downstream of the p38/Mk2 Kinase Complex as a Critical Modulator of Cell Cycle Progression. PLOS ONE. 2015 May 20;10(5):e0125745.
  95. Dietlein F, Thelen L, Jokic M, Jachimowicz RD, Ivan L, Knittel G, Leeser U, van Oers J, Edelmann W, Heukamp LC, Reinhardt HC: A functional cancer genomics screen identifies a druggable synthetic lethal interaction between MSH3 and PRKDC. Cancer Discovery, 2014 May;4(5):592–605.
  96. Huelsemann M, Patz M, Beckmann L, Brinkmann K, Otto T, Fandrey J, Becker H, Theurich S, von Bergwelt-Baildon M, Pallasch C, Zahedi R, Kashkar H, Reinhardt HC, Hallek M, Wendtner CM, Frenzel L: Hypoxia-induced p38 MAPK activation reduces Mcl-1 expression and facilitates sensitivity towards BH3 mimetics in chronic lymphocytic leukemia. Leukemia, 2015 Apr;29(4):981–4.
  97. Dietlein F, Reinhardt HC: Molecular Pathways: Exploiting cancer-specific defects in homology-mediated DNA repair for personalized therapy. Clin Canc Res, 2014 Dec 1;20(23):5882–7.
  98. Dietlein F, Thelen L, Reinhardt HC: Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches. TRENDS in Genetics, 2014 Jul 10. 2014 Aug;30(8):326–39.
  99. Malchers F, Dietlein F, Schöttle J, Lu X, Nogova L, Albus K, Fernandez-Cuesta L, Heuckmann JM, Gautschi O, Diebold J, Plenker D, Gardizi M, Scheffler M, Bos M, Seidel D, Leenders F, Richters A, Peifer M, Florin A, Mainkar PS, Karre N, Chandrasekhar S, George J, Silling S, Rauh D, Zander T, Ullrich R, Reinhardt HC, Ringeisen F, Büttner R, Heukamp LC, Wolf J, Thomas RK: Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer. Cancer Discovery, Published Online First December 3, 2013; doi:10.1158/2159-8290.
  100. Morandell S, Reinhardt HC, Cannell IG, Kim JS, Ruf DM, Jacks T, Yaffe MB: A novel Cre-versible approach identifies synthetic lethal interactions between MK2 and p53 in the DNA damage response in vivo. Cell Reports, 2013 Nov 13. doi:pii: S2211-1247(13)00609-8. 10.1016/j.celrep.2013.10.025.
  101. Franke M, Reinhardt HC, v. Bergwelt-Baildon M, Bangard C: Massive air embolism following lung biopsy. Circulation, 2014 Mar 4;129(9):1046–7.
  102. Reinhardt HC, Yaffe MB. Phosphoserine/threonine binding domains: navigating the cell cycle and DNA damage response. Nat Rev Mol Cell Biol. 2013 Sep;14(9):563–80.
  103. Riabinska A, Daheim M, Herter-Sprie GS, Winkler J, Fritz C, Hallek M, Thomas RK, Kreuzer KA, Frenzel LP, Monfared P, Martins-Boucas JM, Chen S, Reinhardt HC: Therapeutic targeting of a robust non-oncogene addiction to PRKDC in ATM-defective tumors. Sci Transl Med, 2013 Jun 12;5(189):189ra78.
  104. Höpker K, Reinhardt HC: p53-regulating pathways as targets for personalized cancer therapy. Dtsch Med Wochenschr, 2013 Jan;138(3):82–6.
  105. Habbig S, Bartram MP, Sägmüller JG, Franke M, Müller RU, Schwarz R, Hoehne M, Bergmann C, Reinhardt HC, Burst V, Benzing T, Schermer B: The ciliopathy disease protein NPHP9 controls nuclear delivery and activation of the oncogenic transcriptional regulator TAZ, Hum Mol Genet, 2012 Dec 15;21(26):5528–38.
  106. Höpker K, Hagmann H, Khurshid S, Chen S, Schermer B, Benzing T, Reinhardt HC: Putting the brakes on p53-driven apoptosis. Cell Cycle, 2012 Sep 14;11(22).
  107. Boucas J, Höpker K, Chen S, Herter-Sprie GS, Jokic M, Riabinska A, Reinhardt HC: Posttranscriptional regulation of gene expression – adding another layer of complexity to the DNA damage response. Frontiers in Genetics, 2012;3:159.
  108. Höpker K, Hagmann H, Khurshid S, Chen S, Hasskamp P, Seeger-Nukpezah T, Schilberg K, Heukamp L, Lamkemeyer T, Sos M, Thomas R, Lowery D, Fischer M, Roels F, Liebau MC, Resch U, Kisner T, Röther F, Bartram MP, Müller RU, Fabretti F, Kurschat P, Schumacher B, Medema R, Yaffe MB, Schermer B, Reinhardt HC*, Benzing T*: AATF/Che1 acts as a phosphorylation-dependent molecular modulator to repress p53-driven apoptosis. EMBO J, 2012 Oct 17;31(20):3961–75. *equal contribution
  109. Reinhardt HC, Schumacher B: The p53 network: Cellular and systemic DNA damage responses in aging and cancer, TRENDS in Genetics, 2012 Mar;28(3):128–36.
  110. Höhne M, Lorscheider J, Von Bardeleben A, Dufner M, Scharf MA, Gödel M, Helmstädter M, Schurek EM, Zank S, Gerke P, Kurschat C, Sivritas SH, Neumann-Haefelin E, Huber TB, Reinhardt HC, Schermer B, Fischbach KF, Benzing T: The BAR domain protein PICK1 regulates cell recognition and morphogenesis by interacting with Neph proteins. Mol Cell Biol. 2011 Aug;31(16):3241–51.
  111. Herter-Sprie GS, Chen S, Höpker K, Reinhardt HC: Synthetic lethality as a new concept for the treatment of cancer. Dtsch Med Wochenschr, 2011 Jul;136(30):1526-30. Epub 2011 Jul 25.
  112. Chen S, Herter-Sprie GS, Höpker K, Reinhardt HC. The p38/MK2 pathway as a novel target for chemosensitizing therapy. Dtsch Ztsch Klin Forsch, 15 03/04 2011.
  113. Habbig S, Bartram MP, Müller RU, Schwarz R, Andriopoulos N, Chen S, Sägmüller JG, Hoehne M, Burst V, Liebau MC, Reinhardt HC, Benzing T, Schermer B: NPHP4, a cilia-associated protein, negatively regulates the Hippo pathway. J Cell Biol. 2011 May 16;193(4):633–42.
  114. Reinhardt HC, Morandell S, Yaffe MB. Is post-transcriptional stabilization, splicing and translation of selective mRNAs a key to the DNA damage response? Cell Cycle, 2011 Jan 1;10(1):23–7.
  115. Reinhardt HC, Hasskamp P, Schmedding I, Morandell S, van Vugt M, Wang X, Linding R, Ong SE, Weaver D, Carr SA, Yaffe MB: DNA Damage activates A Spatially Distinct Late Cytoplasmic Cell Cycle Checkpoint Network Controlled by MK2-mediated RNA Stabilization. Mol Cell, 2010, 40;1, 34–49, 2010 Oct 8.
  116. van Vugt M, Gardino A, Linding R, Ostheimer G, Reinhardt HC, Ong S-E, Tan C, Maio H, Keezer S, Li R, Pawson T, Lewis T, Carr S, Smerdon S, Brummelkamp T, and Yaffe MB: A Mitotic Phosphorylation Feedback Network Connects Cdk1, Plk1, 53BP1 and Chk2 to Inactivate the G2/M DNA Damage Checkpoint. PLOS Biology, 2010, Jan 26;8(1).
  117. Janes KA*, Reinhardt HC*, Yaffe MB: The Apoptotic Signaling Network Dynamically Interprets the Outputs of Individual Signaling Pathways in an Early Analog and Late Digital Manner. Proceedings of the Uehara Memorial Foundation,in press, *equal contribution
  118. Reinhardt HC, Jiang H, Hemann MT, Yaffe MB: Exploiting synthetic lethal interactions for targeted cancer therapy. Cell Cycle, 2009 Oct 1;8(19):3112–9.
  119. Jiang H*, Reinhardt HC*, Bartkova J, Tommiska J, Blomqvist C, Nevanlinna H, Bartek J, Yaffe MB, Hemann MT: The ATM-Chk2 Signaling Network Controls 
Alternative Cell Fates after Chemotherapy Based on a p53 Binary
Switch. Genes Dev. 2009 Aug 15;23(16):1895–909. *equal contribution
  120. Reinhardt HC, Yaffe MB: Kinases that Control the Cell Cycle in Response to DNA Damage: Chk1, Chk2, and MK2. Curr. Opin. Cell. Biol., 2009 Apr;21(2):245–55.
  121. Janes KA*, Reinhardt HC*, Yaffe MB: Cytokine-induced signaling networks prioritize dynamic range over signal strength. Cell, 2008 Oct 17;135(2):343–54. *equal contribution
  122. Duning K, Schurek EM, Schlüter M, Bayer M, Reinhardt HC, Schwab A, Schaefer L, Benzing T, Schermer B, Saleem MA, Huber TB, Bachmann S, Kremerskothen J, Weide T, Pavenstädt H: KIBRA modulates directional migration of podocytes. J Am Soc Nephrol. 2008 Oct;19(10):1891–903.
  123. Wilker EW, van Vugt MA, Artim SA, Huang PH, Petersen CP, Reinhardt HC, Feng Y, Sharp PA, Sonenberg N, White FM, Yaffe MB: 14-3-3sigma controls mitotic translation to facilitate cytokinesis. Nature. 2007 Mar 15;446(7133).
  124. Reinhardt HC, Aslanian AS, Lees JA, Yaffe MB: p53 deficient cells rely on ATM and ATR-mediated checkpoint signaling through the p38 MAPK/MK2 pathway for survival after DNA damage. Cancer Cell, 2007 Feb;11(2):175–89.
  125. Huber TB, Schermer B, Muller RU, Hohne M, Bartram M, Calixto A, Hagmann H, Reinhardt HC, Koos F, Kunzelmann K, Shirokova E, Krautwurst D, Harteneck C, Simons M, Pavenstadt H, Kerjaschki D, Thiele C, Walz G, Chalfie M, Benzing T: Podocin and MEC-2 bind cholesterol to regulate the activity of associated ion channels. Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17079–17086.
  126. Pache G, Schafer C, Wiesemann S, Springer E, Liebau M, Reinhardt HC, August C, Pavenstadt H, Bek M: Up-regulation of Id-1 via BMP-2 Receptors Induces Re-active Oxygen Species in Podocytes.Am J Physiol Renal Physiol. 2006 Apr 18.
  127. Bek MJ, Reinhardt HC, Fischer KG, Hirsch JR, Hupfer C, Dayal E, Pavenstädt H: Upregulation of early growth response gene-1 via the CXCR3 receptor induces reactive oxygen species and the inhibits Na+/K+-ATPase activity in an immortalized human proximal tubule cell line. J Immunol. 2003 Jan 15; 170(2).
  128. Huber TB*, Reinhardt HC*, Exner M, Burger JA, Kerjaschki D, Saleem MA, Pavenstadt H: Expression of functional CCR and CXCR chemokine receptors in podocytes. J Immunol 2002 Jun 15; 168(12): 6244–52. *equal contribution

Patents

  1. Inventors: Michael B. Yaffe, Isaac A. Manke, Daniel Lim, Hans Christian Reinhardt
    USPTO Application #: 20090010927
    Title: MAPKAP KINASE-2 AS A SPECIFIC TARGET FOR BLOCKING PROLIFERATION OF P53-DEFECTIVE CELLS
  2. Inventors: Manolis Pasparakis, Simon Fallais, Gero Knittel, Hans Christian Reinhardt
    EPO Application #: 20214527.2-1112
    Title: COMBINATION OF INHIBITORS FOR THE PREVENTION AND/OR TREATMENT OF PROLIFERATIVE DISEASES